Will New RaDaR MRD Data and Myeloid Profiling Advances Change NeoGenomics' (NEO) Diagnostics Narrative?

• NeoGenomics, Inc. recently highlighted new clinical data on its RaDaR® 1.0 molecular residual disease assay in early breast cancer and its Neo Comprehensive Myeloid genomic profiling panel at major oncology and hematology conferences, including SABCS 2025 and ASH 2025.
• These presentations underscore how NeoGenomics’ tumor-informed ctDNA testing and comprehensive genomic profiling may sharpen cancer recurrence monitoring, diagnostic accuracy, and treatment selection across solid tumors and myeloid malignancies.
• We’ll now examine how this new RaDaR-focused MRD evidence could influence NeoGenomics’ investment narrative and long-term oncology diagnostics positioning.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe its specialized oncology testing, especially liquid biopsy and MRD, can translate clinical relevance into durable, profitable growth despite current losses and a high fixed cost base. The latest RaDaR and myeloid CGP data support that scientific story, but do not materially change the near term focus on ramping new products like PanTracer while managing portfolio and product mix risk in a competitive NGS market.

The ASH 2025 data on the Neo Comprehensive Myeloid panel look particularly relevant, because they show how NeoGenomics is trying to deepen its footprint in high value myeloid testing. By linking comprehensive genomic profiling to earlier diagnostic refinement and actionable fusions, this readout sits squarely against one of the main catalysts: expanding the menu of advanced tests that can lift revenue per patient and help justify the company’s premium pricing.

Yet beneath this growth story, investors should be aware of the ongoing portfolio and product mix risk, especially if...

Read the full narrative on NeoGenomics (it's free!)

NeoGenomics' narrative projects $893.1 million revenue and $48.1 million earnings by 2028. This requires 9.0% yearly revenue growth and a $152.1 million earnings increase from -$104.0 million today.

Uncover how NeoGenomics' forecasts yield a $13.17 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community valuations for NeoGenomics cluster between US$10.20 and US$19.00, underlining how far opinions can spread on future upside. You should weigh that against the company’s reliance on successful new product ramp up and reimbursement progress, which could have a significant influence on how those expectations play out over time.

Explore 3 other fair value estimates on NeoGenomics - why the stock might be worth 15% less than the current price!

Build Your Own NeoGenomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com